In the original article, there was an error in the CpG oligo-dinucleotide sequence used as adjuvant.
A correction has been made to the section “Materials and Methods”, paragraph “Antibodies and adjuvants”: CpG oligo-dinucleotides 5′-ggTGCATCGATTTATCGATTATCGATGCAGggggg-3′ with lower case letters for phosphorothioate linkages and upper case letters for phosphodiester linkages previously shown to be efficient in pigs (26) were bought from Sigma.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Statements
Conflict of interest
CL, PS, and OS are inventors of the issued patent “A versatile delivery system for antigens or biologically active molecules.” EP 09290987.8-1222, 21.12.09. No license nor royalties. The other authors declare no conflict of interest.
Summary
Keywords
dendritic cells, swine, human, vaccines, routes of administration
Citation
Bernelin-Cottet C, Deloizy C, Stanek O, Barc C, Bouguyon E, Urien C, Boulesteix O, Pezant J, Richard C-A, Moudjou M, Costa BD, Jouneau L, Chevalier C, Leclerc C, Sebo P, Bertho N and Schwartz-Cornil I (2017) Corrigendum: A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies. Front. Immunol. 8:831. doi: 10.3389/fimmu.2017.00831
Received
23 June 2017
Accepted
30 June 2017
Published
18 July 2017
Volume
8 - 2017
Edited and reviewed by
José Mordoh, Fundación Instituto Leloir, Argentina
Updates
Copyright
© 2017 Bernelin-Cottet, Deloizy, Stanek, Barc, Bouguyon, Urien, Boulesteix, Pezant, Richard, Moudjou, Costa, Jouneau, Chevalier, Leclerc, Sebo, Bertho and Schwartz-Cornil.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Isabelle Schwartz-Cornil, isabelle.schwartz@inra.fr
†Present address: Charlotte Deloizy, GenoSafe, Evry, France
Specialty section: This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.